Abstract
Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Current Gene Therapy
Title:The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy
Volume: 15 Issue: 1
Author(s): X.G. Chen and W.T. Godbey
Affiliation:
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Abstract: Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Export Options
About this article
Cite this article as:
Chen X.G. and Godbey W.T., The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127094033
DOI https://dx.doi.org/10.2174/1566523214666141127094033 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies
Anti-Cancer Agents in Medicinal Chemistry Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets The Impact of Antioxidants from the Diet on Breast Cancer Cells Monitored by Raman Microspectroscopy
Letters in Drug Design & Discovery Caspase-8 as a Regulator of Tumor Cell Motility
Current Molecular Medicine Homology Modeling and Docking Studies of Bcl-2 and Bcl-xL with Small Molecule Inhibitors: Identification and Functional Studies
Current Topics in Medicinal Chemistry Androgen Receptor Coregulatory Proteins as Potential Therapeutic Targets in the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Editorial: CPPM 2013 Onward: Building a Socio-Technical GPS for Global Personalized Medicine – A Welcome to Editors-In-Chief Adrian LLerena (Spain) and Ross A. McKinnon (Australia)
Current Pharmacogenomics and Personalized Medicine Nucleo-Cytoplasmic Transport of Proteins as a Target for Therapeutic Drugs
Current Medicinal Chemistry Meet Our Regional Editor
MicroRNA Entropy Model for Multiplex Drug-Target Interaction Endpoints of Drug Immunotoxicity
Current Topics in Medicinal Chemistry Characterization of the Prostaglandin E2 Pathway in a Rat Model of Esophageal Adenocarcinoma
Current Cancer Drug Targets Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Synthesis and Characterization of Magnetite-Polysulfone Micro- and Nanobeads with Improved Chemical Stability in Acidic Media
Current Nanoscience A Case Analysis on CT Guided Percutaneous Lung Puncture Biopsy of Lymphocyte Mesenchymal Pneumonia
Combinatorial Chemistry & High Throughput Screening Protective Effect of Perindopril on Tumor Progression and Angiogenesis in Animal Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry